While covalent drug discovery is reemerging as an important
route
to small-molecule therapeutic leads, strategies for the discovery
and engineering of protein-based irreversible binding agents remain
limited. Here, we describe the use of yeast display in combination
with noncanonical amino acids (ncAAs) to identify irreversible variants
of single-domain antibodies (sdAbs), also called VHHs and nanobodies,
targeting botulinum neurotoxin light chain A (LC/A). Starting from
a series of previously described, structurally characterized sdAbs,
we evaluated the properties of antibodies substituted with reactive
ncAAs capable of forming covalent bonds with nearby groups after UV
irradiation (when using 4-azido-l-phenylalanine) or spontaneously
(when using O-(2-bromoethyl)-l-tyrosine).
Systematic evaluations in yeast display format of more than 40 ncAA-substituted
variants revealed numerous clones that retain binding function while
gaining either UV-mediated or spontaneous crosslinking capabilities.
Solution-based analyses indicate that ncAA-substituted clones exhibit
site-dependent target specificity and crosslinking capabilities uniquely
conferred by ncAAs. Interestingly, not all ncAA substitution sites
resulted in crosslinking events, and our data showed no apparent correlation
between detected crosslinking levels and distances between sdAbs and
LC/A residues. Our findings highlight the power of yeast display in
combination with genetic code expansion in the discovery of binding
agents that covalently engage their targets. This platform streamlines
the discovery and characterization of antibodies with therapeutically
relevant properties that cannot be accessed in the conventional genetic
code.